It can be argued that pathology never exists for pathology's sake-pathogenic mechanisms do not exist solely to induce disease. Instead, they are a reflection of aberrations in normal physiological processes. This notion is beautifully underscored by two recent studies (Lauren et al., 2009; Nikolaev et al., 2009 ) that suggest normal physiological functions for products of the amyloid precursor protein (APP) that may be involved in the pathogenesis of Alzheimer's disease (AD).
The APP-processing pathway is a pathological component of Alzheimer's disease (AD), but there is no consensus regarding the physiological functions of APP and its products. Two studies (Nikolaev et al., 2009; Lauren et al., 2009 ) link the physiological and pathological aspects of APP processing. They show that the APP products, N-APP and Aβ42, are ligands for death receptor 6 and cellular prion protein, respectively, which are important in nervous system development and synaptic suppression. (Left) APP is cleaved by α-secretase or β-secretase, and then by γ-secretase to produce various APP products, including N-terminal APP fragment (N-APP), amyloid-β peptide (Aβ), and APP intracellular domain (AICD). The various fragments perform distinct physiological functions: N-APP induces axonal pruning and neuronal culling by binding to DR6, and Aβ42 oligomers maintain synaptic homeostasis by binding to the prion protein (PrP). (Right) During AD pathogenesis, APP processing is increased or altered by genetic factors such as trisomy 21 in Down's syndrome, mutations in APP, or putative sporadic mechanisms. The resulting increase in Aβ42 and N-APP impairs synaptic plasticity and induces aberrant neuronal and axonal degeneration in a temporal and/or spatial pattern that may be dependent on the expression of the receptors PrP and DR6. Red, genetic factors driving APP processing; blue, possible events inducing sporadic AD; PS1 and PS2, presenilin 1 and 2.
A role for APP processing in AD pathogenesis is supported by findings in patients with familial AD (FAD), a rare but highly aggressive form of AD that is usually inherited in an autosomal dominant manner. All FAD cases identified thus far have mutations in the APP or presenilin genes resulting in increased β-secretase processing and/or enhanced Aβ42 generation (Price et al., 1998) . Individuals with Down's syndrome, who have an extra copy of APP, develop dementia that appears to be clinically identical to AD (Price et al., 1998) .
Although the pathological properties of Aβ42 and to a lesser extent other APP products (Aβ40, C-APP) are under intense investigation, there is no consensus about the specific mechanisms by which they exert these effects. Thus, insights into the physiological functions of APP products, such as identification of physiological interaction partners, may yield answers. Of the proposed physiological functions for APP and its products (reviewed in Mattson, 1997; Thinakaran and Koo, 2008) , the best established is a role for sAPPα in promoting neuronal survival. Other reports link sAPPα to neurite outgrowth, full-length APP to neuronal migration, and the APP intracellular domain (AICD) to transcriptional modulation. Several proteins, including the receptor for advanced glycation end products (RAGE) and the α7 nicotinic acetylcholine receptor, have been proposed to be receptors for Aβ42 (Verdier et al., 2004) . But most proposed physiological functions for APP products, especially neurotrophic functions, are unlikely to explain the pathology that occurs when APP processing is upregulated.
Two recent studies (Lauren et al., 2009; Nikolaev et al., 2009 ) now connect the physiological and pathological functions of APPprocessing products. Lauren et al. show that Aβ42 binds to the cellular prion protein (PrP), which itself can cause neuropathology when misfolded. In a separate study, Nikolaev et al. report that the N-terminal fragment of APP (N-APP) interacts with death receptor 6 (DR6), resulting in pruning of axons and neurons during development of the central nervous system (CNS).These studies suggest that APP processing constitutes a complex signaling center that serves multiple physiological functions that could trigger pathological events when deregulated during disease.
Aβ42, Prion Protein, and Synaptic Suppression
Loss of synapses and synaptic activity is thought to underlie the progressive cognitive decline seen in AD. Transgenic mice overexpressing APP carrying FAD mutations appear to successfully recapitulate this aspect of AD, exhibiting synaptic dysfunction and behavioral deficits (Price et al., 1998) . Organotypic cultures from these mice display impairments in long-term potentiation (LTP), a measure of the strengthening of synaptic connections after electrical stimulation that is the basis of learning and memory. Aggregates of Aβ42 are postulated to be responsible for this effect, and nanomolar concentrations of Aβ42 oligomers can block LTP, trigger synaptic retraction, and cause impairments in learning and memory in rodents (Hardy and Selkoe, 2002) .
Direct mechanisms underlying the synaptotoxic (synaptic inhibitory) functions of Aβ42 aggregates have not been clearly demonstrated; there has been some speculation that Aβ42 aggregates "gum up" synapses, that is, block synaptic function through obstruction. Now, Lauren et al. (2009) uncover a molecular basis for Aβ42's antisynaptic function by identifying a specific receptor for oligomeric Aβ42 that mediates its effects on LTP suppression.
They devised an elegant screen based on the simple observation that Aβ42 oligomers bind to cultured hippocampal neurons with high affinity but not to COS-7 cells. This enabled them to screen a mouse brain complementary DNA (cDNA) library for genes that allow Aβ42 oligomers to bind to COS-7 cells. From 225,000 clones, two positive clones were isolated, both encoding PrP. Aβ42 oligomers bind to PrP with high affinity and specificity. Aβ42 either did not bind to RAGE or the α7 nicotinic acetylcholine receptor or bound with very low affinity. Nanomolar concentrations of oligomeric Aβ42 potently inhibited LTP, but this effect could be abrogated either in the absence of PrP or by blocking the Aβ42-PrP interaction with antibodies against the Aβ42-binding region. Thus, the authors provide compelling evidence that PrP is a specific binding partner for Aβ42 oligomers and mediates Aβ42's inhibitory effect on synaptic plasticity. This finding fits well with previous reports that independently implicate Aβ42 and PrP in synaptic function (Westergard et al., 2007) . Thus, the Aβ42-PrP signaling pathway may be at play in the cognitive impairment of AD, and PrP may constitute a new therapeutic target. The high affinity and specificity of the Aβ42-PrP interaction suggests that rather than being a "random encounter" with pathological consequences, this interaction and the subsequent suppression of synaptic activity may serve a physiological purpose. Indeed, the notion of a physiological function for Aβ42 in synaptic suppression has been suggested before. Induction of synaptic activity in organotypic cultures enhances Aβ42 (and Aβ40) generation, which appears to act as a negative feedback loop in excitatory synaptic transmission (Kamenetz et al., 2003) . Hinting at a physiological role for synaptic activity-driven negative feedback, mice lacking APP are more sensitive to seizures induced by the drug kainate. PrP may also play an inhibitory role in excitatory synaptic transmission, and protects against excitotoxic damage in vivo (Khosravani et al., 2008) . Thus, the Aβ42-PrP interaction may serve a physiological purpose in maintaining synaptic homeostasis and in guarding against excessive excitation. The excess generation and extracellular accumulation of Aβ42 encountered in AD could lead to a pathological suppression of synaptic activity.
When considering either the physiological or pathological role of the Aβ42-PrP interaction, it will be necessary to obtain definitive identification of the responsible Aβ42 oligomers, as well as their characterization and quantification in AD and non-AD brain tissue. Also, it is still undetermined whether the low levels of oligomeric Aβ42 in non-AD human or mouse brains would be sufficient to modulate PrP signaling. It is possible that even minute levels of oligomeric Aβ42 could trigger suppression of synaptic activity if concentrated within the synapse. Alternatively, Aβ42-PrP signaling may be a safeguard mechanism that is only activated during heightened synaptic activity (and increased Aβ42) encountered, for example, during an epileptic seizure or excitotoxic event. Interestingly, picomolar concentrations of Aβ42 can actually enhance LTP (Puzzo et al., 2008) , further supporting a physiological role for Aβ42 in synaptic homeostasis, but indicating that our understanding of Aβ42′s role in synaptic plasticity is far from complete.
What are the downstream mechanisms by which the Aβ42-PrP interaction impairs LTP? Although PrP interacts with and inhibits NMDA receptor subunit 2D (Khosravani et al., 2008) , Lauren et al. (2009) observed that this receptor is insensitive to Aβ42 oligomers when expressed in frog oocytes. As this is a heterologous Cell 137, June 12, 2009 ©2009 Elsevier Inc. 999 system, one cannot rule out that the Aβ42-PrP interaction may inhibit NMDA receptor subunit 2D or other glutamate receptors in the presence of neuron-specific components. Also, Lauren and coworkers found that PrP and its binding to Aβ42 oligomers is localized predominantly in dendrites and at postsynaptic terminals. However, PrP also may be concentrated at presynaptic terminals (Westergard et al., 2007) , and thus both pre-and postsynaptic mechanisms should be considered. One possibility is that Aβ42 may compete with synaptic proteins for binding to PrP.
Crossing PrP-deficient mice with transgenic mice carrying FAD mutations will reveal whether AD-relevant synaptic and behavioral deficits can be rescued by PrP deficiency in vivo. Another intriguing question is whether Aβ42-PrP signaling is important for synaptic pruning during normal development given that APP, APP-processing enzymes, and PrP are expressed in a spatial and temporal manner that parallels this process. Interestingly, a specific polymorphism in PrP appears to reduce the risk of developing AD (Bertram and Tanzi, 2008) . Might this polymorphism affect PrP's interaction with Aβ42?
N-APP and DR6 in Development
In their new study, Nikolaev et al. (2009) uncover a physiological function for the APP-processing product N-APP in developmental pruning and culling of neurons. Their study suggests an alternative, although mutually compatible, view of AD pathogenesis. Although progressive neuronal loss and neurite degeneration are key features of AD and other neurodegenerative disorders, the fact that neuronal and neurite loss occurs normally in the developing brain is often overlooked. Excess neurons are born during development of the nervous system, and 50% or more are subsequently eliminated in a manner dependent on neurotrophic support (or lack thereof) (Raff et al., 1993) . Similarly, the formation of axons during development is generally exuberant, but then axons undergo trophic factor-dependent pruning to achieve precise neural connectivity (Luo and O'Leary, 2005) . The process of excessive connectivity followed by trophic factor-based selection and elimination is thought to ensure the robust yet specific formation of proper connections and circuitry in the CNS. Depending on the specific context, there may be small-scale axonal pruning, large-scale axonal pruning, or death of the entire neuron. The molecular mechanisms underlying this culling process are under investigation, but Trk receptors, the p75 neurotrophin receptor, and components of the death receptor pathways are emerging as important players (Luo and O'Leary, 2005) .
It is not clear whether, or to what extent, pruning of axons and culling of neurons takes place in AD. Thus far, axonal transport defects, distended axons, and axonal dystrophy have been reported in AD brain tissue rather than the large-scale axon elimination seen in developmental pruning. Similarly, it is unclear how much of a role the extrinsic apoptosis pathway plays in AD, given that contributions from different types of neuronal loss (necrotic, apoptotic, necroptotic) are still under debate (Ellis et al., 1991) .
On the other hand, some of the signaling components involved in developmental pruning/culling appear to be activated during AD. For example, altered expression of neurotrophins and their receptors has been reported (Schindowski et al., 2008) , and neurotrophic factors have been administered in mouse models and clinical trials to delay neurodegeneration (Tuszynski et al., 2005) , suggesting that trophic support-dependent survival or elimination mechanisms may be at work in AD. Interestingly, mice overexpressing an antibody against nerve growth factor exhibit AD-like features, including plaques and tangles (Capsoni et al., 2000) . Other pruning/culling components implicated in AD pathogenesis include the Fas death receptor (CD95), TNF receptors, and the p75 receptor. However, as these signaling pathways are also upregulated in response to neuronal injury, it is uncertain whether these components contribute to primary causative mechanisms or reflect secondary processes such as neuroinflammation.
Shedding new light on the matter, Nikolaev and colleagues reveal a physiological mechanism in which an APP product (N-APP) binds directly to a death receptor to trigger axonal pruning and neuronal culling during development. These processes are thought to be activated by a lack of trophic factors, so depriving primary embryonic neurons of trophic factors is a popular system for examining the culling of neurons and axons. Using this system and genetic mouse models, the authors determined that DR6 is required for the timely pruning of axons and the elimination of neurons during spinal cord or retinal development in vivo and in trophic factor-deprived neuronal cultures. DR6-dependent axonal pruning is mediated by caspase 6 and neuronal culling by caspase 3. Trophic factor deprivation induced cleavage of APP by β-secretase, resulting in formation of sAPPβ and subsequently N-APP. Surprisingly, N-APP acts as a necessary and sufficient ligand for DR6, inducing axonal and neuronal degeneration after trophic factor removal. However, neither inhibition of α-secretase nor antibody-mediated blocking of Aβ42 affected this pathway, although Aβ42 did trigger axonal degeneration in a DR6-independent manner. An oversprouting axon phenotype similar to that in mice lacking DR6 was seen in mice lacking both APP and a closely related protein, APLP2, further supporting a role in pruning. Collectively, the authors demonstrate a new signaling module involving N-APP and DR6 that is activated by the β-secretase BACE1, and that triggers the degeneration of axons and neurons lacking sufficient trophic support.
How does this mechanism fit with our current view of AD pathogenesis? The finding that N-APP rather than Aβ42 binds to DR6 implicates a new nonamyloid APP product in AD. On the other hand, roles for N-APP and Aβ42 in AD are not necessarily exclusive, and may even work in conjunction. Aβ42 may mediate suppression of LTP, whereas N-APP may induce axonal degeneration and neuronal loss. Although Aβ42 does not act as a DR6 ligand, inhibitors of γ-secretase partly block trophic deprivation-induced axonal degeneration, raising the possibility that γ-secretase activity somehow feeds into this signaling mechanism. Further examination of the relationships between these two divergent branches of APP processing is warranted. There are also questions about the formation of the mysterious N-APP fragment, which appears to be sufficient to induce trophic deprivation-induced degeneration of neurons. Trophic factor deprivation strongly induced N-APP formation in a β-secretase-dependent manner. What mechanisms during trophic deprivation-induced pruning could result in the dramatic and specific induction of β-secretase activity? Once sAPP species are made, what cleaves sAPP to generate the N-APP ligand? Is this cleavage an obligatory step? Finally, are N-APP levels increased in AD brain tissue, and, if so, at which stage of the disease?
This study may also provide tools to examine a critical unresolved question in AD: what determines susceptibility? A central mystery is the age-dependent nature of AD and that certain brain regions are more susceptible than others. Could region-specific or age-dependent expression of N-APP or DR6, or trophic factor availability, determine susceptibility to AD? Do risk factors associated with AD, such as prior brain injury or stroke, lead to upregulation of N-APP or DR6? Transgenic mice overexpressing APP carrying FAD mutations (which may have high levels of N-APP) display synaptic dysfunction but not overt neurodegeneration. What permissive environment is required to trigger neurodegeneration in these mice? The authors report that trophic factors can act both upstream and downstream of N-APP-DR6 signaling; as downstream components, they provide a "fail-safe" mechanism to prevent degeneration even in the presence of N-APP and DR6. Could trophic factor availability determine susceptibility to AD in a manner analogous to the competitive survival of neurons during development? The Nikolaev et al. findings provide substance to the intriguing idea that AD may be a disease of the aberrant deployment of pruning and culling mechanisms that operate during development. This study provides specific molecules and signaling events that can be investigated in future studies and pinpoints DR6, caspase 6, and the sAPPβ-to-N-APP cleavage event as potential therapeutic targets.
APP in Physiology and Pathology
Early observations of amyloid plaques (and neurofibrillary tangles) as defining features of AD pathology, and the subsequent characterization of fibrillar amyloid deposits in plaques, has led to the view that AD is an "amyloidopathy" and a disease of protein misfolding and aggregation. This perspective emphasizes a toxic gain-of-function mechanism based on the propensity of Aβ to form insoluble fibrils that is unrelated to a physiological role for Aβ or other APP products. Lately, it has been suggested that the extensive fibrillar aggregates found in amyloid plaques may not be directly related to AD etiology, and that early-stage Aβ aggregates, such as oligomers, may be more relevant to pathogenesis. Also, APP and its products are increasingly recognized as playing important physiological roles in the brain. Might the underlying causes of AD be more related to the physiological roles of Aβ and other APP products than previously appreciated?
APP may have a range of physiological functions associated with developing and adult neurons that are modulated through its sequential processing pathways and mediated through specific interactions with cell-surface proteins (for secreted species) and intracellular proteins (for AICD) (Figure 1 ). This scheme is complex, depending not only on modulation of enzyme expression and activity but also on the intricate modulation of substrate-enzyme interactions. For example, it remains to be determined whether trophic deprivation induces shedding of surface APP through upregulation of BACE1, altered distribution of APP or BACE1 in the endocytosis pathway, or a combination of multiple factors.
In AD, it is clear that this complex network of APP processingbased signaling is altered and hyperactivated. This could stem from genetic factors such as APP mutations or from sporadic factors. Accumulation of APP products, in particular Aβ42 and N-APP, may trigger synaptic suppression and neurodegeneration, resulting in AD pathogenesis. Importantly, these actions of Aβ42 and N-APP may depend on the expression and accessibility of their receptors, PrP and DR6, respectively, and of downstream components, a prerequisite that may underlie the age-dependent and brain region-dependent susceptibility of AD. A critical, unanswered question is why and how APP processing is upregulated in sporadic AD. Perhaps important insights may be gleaned from the induction of β-secretase activity by trophic factor deprivation, as Nikolaev and coworkers observed.
These ideas, of course, are speculative, but nonetheless the findings of the two new studies should goad us to reconsider how we view AD. They suggest that distinct "suppressive" or "degenerative" roles for APP products that normally serve a useful function could cause AD when ectopically or excessively activated in the aged human brain. It is cautiously anticipated that subsequent studies will fill in the necessary gaps and complete the bridge between the physiology and pathology of AD, and with it a blueprint for a cure.
